Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort-Reference-Cited by-同舟云学术

Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort

Published:2020-03-05 Issue:7 Volume:69 Page:1177-1187
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Naqash Abdul Rafeh,Ricciuti Biagio,Owen Dwight H.,Florou Vaia,Toi Yukihiro,Cherry Cynthia,Hafiz Maida,De Giglio Andrea,Muzaffar Mavish,Patel Sandip H.,Sugawara Shunichi,Burkart Jarred,Park Wungki,Chiari Rita,Sugisaka Jun,Otterson Gregory A.,de Lima Lopes Gilberto,Walker Paul R.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1007/s00262-020-02536-5.pdf

Reference33 articles.

1. Wei SC, Duffy CR, Allison JP (2018) Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov 8(9):1069–1086. https://doi.org/10.1158/2159-8290.cd-18-0367

2. Doroshow DB, Sanmamed MF, Hastings K, Politi K, Rimm DL et al (2019) Immunotherapy in non-small cell lung cancer: facts and hopes. Clin Cancer Res 25(15):4592–4602. https://doi.org/10.1158/1078-0432.CCR-18-1538

3. Vokes EE, Ready N, Felip E, Horn L, Burgio MA et al (2018) Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases. Ann Oncol 29(4):959–965. https://doi.org/10.1093/annonc/mdy041

4. Young A, Quandt Z, Bluestone JA (2018) The balancing act between cancer immunity and autoimmunity in response to immunotherapy. Cancer Immunol Res 6(12):1445–1452. https://doi.org/10.1158/2326-6066.CIR-18-0487

5. Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378(2):158–168. https://doi.org/10.1056/NEJMra1703481

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association of Immune-Related Adverse Events and the Efficacy of Anti–PD-(L)1 Monotherapy in Non–Small Cell Lung Cancer: Adjusting for Immortal-Time Bias;Cancer Research and Treatment;2024-07-15

2. Safety, efficacy, and survival outcomes of immune checkpoint inhibitors rechallenge in patients with cancer: a systematic review and meta-analysis;The Oncologist;2024-06-28

3. Association between immune-related adverse events and prognosis in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis;Frontiers in Oncology;2024-05-08

4. Immune checkpoint inhibitor‑associated diabetes mellitus in patients with HCC: Report of three cases and literature review;Experimental and Therapeutic Medicine;2024-03-12

5. PD-1/PD-L1 inhibitor-induced immune thrombocytopenia: A pharmacovigilance study and systematic review;International Immunopharmacology;2024-03